Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. V.P., Regulatory Affairs | February 23, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date February 23, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 86,933 |
Ending reported balance
After 2024-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-23 · Grant · Acquired 1,250 · Balance 87,418 Row 2 · 2024-02-23 · Tax withholding · Disposed 485 · Balance 86,933 F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 3,750 |
Reported balance
After 2024-02-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-23 · Disposition to issuer · Disposed 1,250 · Balance 3,750 F2: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting.
F2: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
F3: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2024 Filed Feb 27, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028269 · tm247055-24_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 485 | $29.06 | $14,094.10 |
DisclosureSEC source: 0001104659-24-028269 · tm247055-24_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,933 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-028269 · tm247055-24_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,418 Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027564 · tm247055-2_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 246 | $27.94 | $6,873.24 |
DisclosureSEC source: 0001104659-24-027564 · tm247055-2_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,168 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027564 · tm247055-2_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,414 Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-24-003741 · tm243247-1_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on January 21, 2015. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 8,000 | $27.91 | $223,280.00 |
DisclosureSEC source: 0001104659-24-003741 · tm243247-1_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,664 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.69 to $28.22, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 10, 2024 Filed Jan 12, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,000 | $9.24 | $73,920.00 |
DisclosureSEC source: 0001104659-24-003741 · tm243247-1_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023. F2 · balance_after: Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,100 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-23-097813 · tm2325321-1_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,900 Underlying: Common Stock · 8,100 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 21, 2021. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 8,100 | $32.00 | $259,200.00 |
DisclosureSEC source: 0001104659-23-097813 · tm2325321-1_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,249 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,100 | $23.99 | $194,319.00 |
DisclosureSEC source: 0001104659-23-097813 · tm2325321-1_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 29, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,135 | $31.59 | $162,214.65 |
DisclosureSEC source: 0001104659-23-096582 · tm2325057-1_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,249 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.38 to $31.92, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. F2 · balance_after: Includes an aggregate of 350 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026085 · tm237737-18_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026085 · tm237737-18_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025370 · tm237737-8_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025370 · tm237737-8_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,323 F1 · balance_after: Includes an aggregate of 853 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:00 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044664 · tm2312277-2_4aseq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 750 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:00 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 289 | $38.57 | $11,146.73 |
DisclosureSEC source: 0001104659-23-044664 · tm2312277-2_4aseq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,034 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:00 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044664 · tm2312277-2_4aseq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,323 F1 · balance_after: Includes an aggregate of 853 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023834 · tm237193-3_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On April 30, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023834 · tm237193-3_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004289 · tm233672-2_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F1 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-22-093748 · tm2223647-3_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $35.98 | $179,900.00 |
DisclosureSEC source: 0001104659-22-093748 · tm2223647-3_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,220 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:16 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $7.90 | $39,500.00 |
DisclosureSEC source: 0001104659-22-093748 · tm2223647-3_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:31 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-22-086723 · tm2222645-2_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:31 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,000 | $32.98 | $164,900.00 |
DisclosureSEC source: 0001104659-22-086723 · tm2222645-2_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,220 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 20:31 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,000 | $7.90 | $39,500.00 |
DisclosureSEC source: 0001104659-22-086723 · tm2222645-2_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,220 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026873 · tm227622-11_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026873 · tm227622-11_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:17 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027398 · tm227764-5_4aseq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. F4 · derivative.expiration_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:17 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-027398 · tm227764-5_4aseq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-02-22 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 00:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,125 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-21-050369 · tm2113039-1_4seq1.xml · derivative · entry 6 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 3,125 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 00:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,125 | $31.98 | $99,937.50 |
DisclosureSEC source: 0001104659-21-050369 · tm2113039-1_4seq1.xml · nonDerivative · entry 4 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,326 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021. Read SEC document |
| April 14, 2021 Filed Apr 15, 2021 00:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,125 | $12.98 | $40,562.50 |
DisclosureSEC source: 0001104659-21-050369 · tm2113039-1_4seq1.xml · nonDerivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 00:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,125 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-21-050369 · tm2113039-1_4seq1.xml · derivative · entry 5 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,375 Underlying: Common Stock · 3,125 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021. F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 00:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,125 | $29.98 | $93,701.88 |
DisclosureSEC source: 0001104659-21-050369 · tm2113039-1_4seq1.xml · nonDerivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,326 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021. Read SEC document |
| April 13, 2021 Filed Apr 15, 2021 00:24 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,125 | $12.98 | $40,562.50 |
DisclosureSEC source: 0001104659-21-050369 · tm2113039-1_4seq1.xml · nonDerivative · entry 1 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 11, 2021. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:54 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001104659-21-026937 · tm217706-9_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2031-02-19 F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2022. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 23:33 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-20-024915 · a4.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2030-02-21 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.